Class summary at a glance.

Every drug in the Ergot Derivative class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $23.1Mcombined across class
Total Rx claims: 195K54K unique beneficiaries
Generic mfrs (active): 17across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Bromocriptine

Brand: CYCLOSET · 57K Part D claims (CY24) · 13K beneficiaries · First FDA approval: 1998-01-13

4 generic mfrs 1 plans require PA

Low NADAC$1.65

→

Avg plan cost$3.02

Part D spend $12.5M 2× spread, current vs floor

Class share

54%

of class CY24 spend

View profile →

Cabergoline

138K Part D claims (CY24) · 41K beneficiaries · First FDA approval: 2007-03-07

5 generic mfrs 0 plans require PA

Low NADAC$1.41

→

Avg plan cost$1.41

Part D spend $10.1M 1× spread, current vs floor

Class share

44%

of class CY24 spend

View profile →

Methylergonovine

Brand: Methergine · 287 Part D claims (CY24) · 117 beneficiaries · First FDA approval: 2010-06-21

8 generic mfrs

Low NADAC$5.66

→

Avg plan cost$5.66

Part D spend $503249 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.